Cost Matters Not Just in Cancer Care But In Other Diseases Too – Forbes

nemasket.net

Further to the op-ed by Memorial Sloan-Kettering oncologists (A Hospital Says ‘No’ to an $11,000-a-Month Cancer Drug), more on how cost considerations are increasingly playing a role in deciding which drugs to use, and the requirement for better outcomes and benefits to justify additional cost. Quote:

The Ben Goldacres of the world will claim that biopharmaceutical companies run minimal clinical trials to get drugs approved. That might have been the case years ago, but that’s not acceptable now. Physicians, payers and even patients are demanding that the expensive drugs that are prescribed deliver value. Sanofi and Regeneron are feeling that pressure today – as will others who can’t demonstrate the value of their new drug over existing treatments. The MSKCC oncologists may have drawn a line in the sand, but this line has been years in the making

Cost Matters Not Just in Cancer Care But In Other Diseases Too – Forbes.

Advertisements

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s